UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
Amendment No.1
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) January 19, 2004
ENZON PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware 0-12957 22-2372868
(State or other jurisdiction of (Commission (IRS Employer
incorporation) File Number) Identification)
685 Route 202/206, Bridgewater, New Jersey 08807
(Address of principal executive offices) (Zip Code)
(Registrant's telephone number, including area code: (908) 541-8600
----------------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 5. Other Events
On January 21, 2004, Enzon Pharmaceuticals, Inc. ("Enzon") filed a Current
Report on Form 8-K (the "Original Form 8-K") to report a strategic partnership
with Inex Pharmaceuticals Corporation ("INEX") to develop and commercialize
INEX's proprietary oncology product Onco TCS. The disclosure set forth in Item 5
of the Original Form 8-K contained a typographical error stating that INEX
received a US$10 million up-front payment. The correct amount of the up-front
payment was $12 million, as was correctly set forth in the press release
announcing the transaction issued by Enzon and filed as an exhibit to the
Original Form 8-K.
This amendment continues to speak as of the date of the filing of the
Original Current Report, and the Registrant has not updated the disclosures
contained herein to reflect any events that occurred at a later date.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
Dated: February 03, 2004
By: /s/ Kenneth J. Zuerblis
-----------------------------
Kenneth J. Zuerblis
Vice President, Finance and
Chief Financial Officer